86 related articles for article (PubMed ID: 35571606)
1. Real-world outcomes of adjuvant gemcitabine
Kang S; Yoo C; Lee SH; Oh D; Song TJ; Lee SS; Jeong JH; Park DH; Seo DW; Park JH; Hwang DW; Song KB; Lee JH; Lee W; Kwak BJ; Hong S; Chang HM; Ryoo BY; Kim KP; Kim SC
Ther Adv Med Oncol; 2022; 14():17588359221097190. PubMed ID: 35571606
[TBL] [Abstract][Full Text] [Related]
2. Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma.
de Jong EJM; Janssen QP; Simons TFA; Besselink MG; Bonsing BA; Bouwense SAW; Geurts SME; Homs MYV; de Meijer VE; Tjan-Heijnen VCG; van Laarhoven HWM; Valkenburg-van Iersel LBJ; Wilmink JW; van der Geest LG; Koerkamp BG; de Vos-Geelen J;
Int J Cancer; 2022 May; 150(10):1654-1663. PubMed ID: 34935139
[TBL] [Abstract][Full Text] [Related]
3. A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea.
Lee HS; Chung MJ; Park JY; Bang S; Park SW; Kim HG; Noh MH; Lee SH; Kim YT; Kim HJ; Kim CD; Lee DK; Cho KB; Cho CM; Moon JH; Kim DU; Kang DH; Cheon YK; Choi HS; Kim TH; Kim JK; Moon J; Shin HJ; Song SY;
Medicine (Baltimore); 2017 Jan; 96(1):e5702. PubMed ID: 28072706
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.
Herrmann R; Bodoky G; Ruhstaller T; Glimelius B; Bajetta E; Schüller J; Saletti P; Bauer J; Figer A; Pestalozzi B; Köhne CH; Mingrone W; Stemmer SM; Tàmas K; Kornek GV; Koeberle D; Cina S; Bernhard J; Dietrich D; Scheithauer W; ;
J Clin Oncol; 2007 Jun; 25(16):2212-7. PubMed ID: 17538165
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of gemcitabine plus capecitabine in the treatment of advanced or metastatic pancreatic cancer: a systematic review and meta-analysis.
Xiao BY; Wang BC; Lin GH; Li PC
Ann Palliat Med; 2020 Jul; 9(4):1631-1642. PubMed ID: 32576005
[TBL] [Abstract][Full Text] [Related]
6. A systematic review and network meta-analysis of phase III randomised controlled trials for adjuvant therapy following resection of pancreatic ductal adenocarcinoma (PDAC).
Kamarajah SK; Bundred JR; Alrawashdeh W; Manas D; White SA
HPB (Oxford); 2020 May; 22(5):649-659. PubMed ID: 31894014
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy of modified FOLFIRINOX, gemcitabine plus capecitabine and gemcitabine plus nab-paclitaxel as adjuvant treatment for resected pancreatic cancer: a Bayesian network meta-analysis.
de Jesus VHF; Riechelmann RP
Ecancermedicalscience; 2021; 15():1276. PubMed ID: 34567261
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine and Taxane Adjuvant Therapy with Chemoradiation in Resected Pancreatic Cancer: A Novel Strategy for Improved Survival?
Kanji ZS; Edwards AM; Mandelson MT; Sahar N; Lin BS; Badiozamani K; Song G; Alseidi A; Biehl TR; Kozarek RA; Helton WS; Picozzi VJ; Rocha FG
Ann Surg Oncol; 2018 Apr; 25(4):1052-1060. PubMed ID: 29344878
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant nab-paclitaxel plus gemcitabine
Yin ZZ; Zhao ZM; Tang WB; Jiang N; Zhang KD; Song YY; Wang Y; Li CG; Gao YX; Liu R
World J Clin Cases; 2020 Jul; 8(13):2778-2786. PubMed ID: 32742988
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer.
Courtin A; Richards FM; Bapiro TE; Bramhall JL; Neesse A; Cook N; Krippendorff BF; Tuveson DA; Jodrell DI
PLoS One; 2013; 8(6):e67330. PubMed ID: 23840665
[TBL] [Abstract][Full Text] [Related]
11. Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical Trial.
Nicolle R; Bachet JB; Harlé A; Iovanna J; Hammel P; Rebours V; Turpin A; Ben Abdelghani M; Wei A; Mitry E; Lopez A; Biagi J; François E; Artru P; Lambert A; Renouf DJ; Monard L; Mauduit M; Dusetti N; Conroy T; Cros J
J Clin Oncol; 2024 Mar; 42(9):1067-1076. PubMed ID: 37963313
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data.
Giovinazzo F; Soggiu F; Jang JY; Versteijne E; van Tienhoven G; van Eijck CH; Han Y; Choi SH; Kang CM; Zalupski M; Ahmad H; Yentz S; Helton S; Rose JB; Takishita C; Nagakawa Y; Abu Hilal M
Front Oncol; 2020; 10():1112. PubMed ID: 32850319
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of gemcitabine-capecitabine combination therapy for pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials.
Ouyang G; Wu Y; Liu Z; Lu W; Li S; Hao S; Pan G
Medicine (Baltimore); 2021 Dec; 100(48):e27870. PubMed ID: 35049189
[TBL] [Abstract][Full Text] [Related]
14. Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world study.
Li H; Guo Y; Sun X; Lu Y; Chang S; Wang X; Gao S; Gao C; Zhao T
Front Oncol; 2023; 13():1276037. PubMed ID: 37909023
[TBL] [Abstract][Full Text] [Related]
15. Comparison of adjuvant gemcitabine plus S-1 with S-1 monotherapy for pancreatic ductal adenocarcinoma: Retrospective real-world data.
Tang H; Qiao C; Lu J; Cheng Y; Dai M; Zhang T; Guo J; Wang Y; Bai C
Neoplasia; 2022 Dec; 34():100841. PubMed ID: 36265240
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of patients with borderline resectable and resectable pancreatic adenocarcinoma treated with neoadjuvant three-week course chemoradiotherapy using capecitabine-based versus gemcitabine-based concurrent chemotherapy.
Neibart SS; Mamidanna S; Chundury A; Sayan M; Alexander HR; August DA; Berim LD; Boland PM; Grandhi MS; Gulhati P; Hochster HS; Langan RC; Spencer KR; Kennedy TJ; Deek MP; Jabbour SK
J Gastrointest Oncol; 2021 Dec; 12(6):2557-2566. PubMed ID: 35070387
[TBL] [Abstract][Full Text] [Related]
17. Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer?
Fenocchio E; Filippi R; Lombardi P; Quarà V; Milanesio M; Aimar G; Leone F; Aglietta M
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31614884
[TBL] [Abstract][Full Text] [Related]
18. Real-world patterns of adjuvant chemotherapy treatment for patients with resected pancreatic adenocarcinoma.
Abdel-Rahman O; Spratlin J; Koski S
Med Oncol; 2021 Feb; 38(2):18. PubMed ID: 33534008
[TBL] [Abstract][Full Text] [Related]
19. Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy.
Mortier V; Wei F; Pellat A; Marchese U; Dohan A; Brezault C; Barat M; Fuks D; Soyer P; Coriat R
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551662
[TBL] [Abstract][Full Text] [Related]
20. Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe.
Javed MA; Beyer G; Le N; Vinci A; Wong H; Palmer D; Morgan RD; Lamarca A; Hubner RA; Valle JW; Alam S; Chowdhury S; Ma YT; Archibugi L; Capurso G; Maisonneuve P; Neesse A; Sund M; Schober M; Krug S
Pancreatology; 2019 Jan; 19(1):97-104. PubMed ID: 30529068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
